Intrexon Corporation (NYSE:XON) shares gapped up before the market opened on Thursday . The stock had previously closed at $12.37, but opened at $12.65. Intrexon Corporation shares last traded at $13.62, with a volume of 2971409 shares traded.
XON has been the topic of several recent research reports. Northland Securities reiterated a “buy” rating and set a $27.00 price objective on shares of Intrexon Corporation in a research report on Friday, October 6th. BidaskClub cut Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Bank of America Corporation decreased their price target on Intrexon Corporation from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Griffin Securities restated a “buy” rating and issued a $55.00 price target on shares of Intrexon Corporation in a research report on Friday, October 6th. Finally, JMP Securities restated an “outperform” rating and issued a $42.00 price target on shares of Intrexon Corporation in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.50.
The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85.
Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Intrexon Corporation by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock valued at $106,811,000 after acquiring an additional 147,517 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after acquiring an additional 54,179 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Intrexon Corporation in the second quarter valued at about $593,000. Trellus Management Company LLC bought a new position in Intrexon Corporation in the third quarter valued at about $475,000. Finally, Bank of New York Mellon Corp grew its position in Intrexon Corporation by 7.1% in the second quarter. Bank of New York Mellon Corp now owns 234,139 shares of the biotechnology company’s stock valued at $5,640,000 after acquiring an additional 15,568 shares during the last quarter. Hedge funds and other institutional investors own 77.28% of the company’s stock.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
What are top analysts saying about Intrexon Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intrexon Corporation and related companies.